Literature DB >> 18241672

Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer.

Joanna Narkiewicz1, Dagmara Klasa-Mazurkiewicz, Dorota Zurawa-Janicka, Joanna Skorko-Glonek, Janusz Emerich, Barbara Lipinska.   

Abstract

OBJECTIVES: Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes was examined in ovarian tissue specimens including 19 normal ovaries, 20 benign tumors, 7 borderline tumors, 44 cancers and 8 Krukenberg tumors. DESIGN AND METHODS: mRNA and protein levels were evaluated by semi-quantitative RT-PCR and Western-blotting methods, respectively.
RESULTS: A statistically significant decrease of HtrA1 and HtrA3 expression in ovarian tumors comparing to normal tissues was observed. A dramatic decrease of HtrA3 mRNA and protein levels in all tumor tissue groups, and a loss of HtrA3 protein in 30% malignant tumors were found. A significant decrease of HtrA1 mRNA, and of HtrA3 mRNA and protein in malignant tumors compared to benign tumors was revealed. HtrA2 expression in tumor tissues was slightly decreased. Expression of TGF-beta1 in tumor tissues was not significantly different compared to control tissues.
CONCLUSIONS: Our results show downregulation of HtrA1 and HtrA3 genes' expression in different types of ovarian tumors and give additional evidence that these genes may function as tumor suppressors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18241672     DOI: 10.1016/j.clinbiochem.2008.01.004

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  24 in total

1.  Elevated serine protease HtrA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-κB signaling pathway.

Authors:  Jin Xia; Feng Wang; Liuxing Wang; Qingxia Fan
Journal:  Tumour Biol       Date:  2012-10-19

2.  Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.

Authors:  Hiroaki Soyama; Morikazu Miyamoto; Masashi Takano; Tadashi Aoyama; Hiroko Matsuura; Takahiro Sakamoto; Kazuki Takasaki; Mika Kuwahara; Kento Kato; Tomoyuki Yoshikawa; Hideki Iwahashi; Hitoshi Tsuda; Kenichi Furuya
Journal:  Med Oncol       Date:  2017-11-22       Impact factor: 3.064

3.  HtrA3 is negatively correlated with lymph node metastasis in invasive ductal breast cancer.

Authors:  Yongxiang Yin; Man Wu; Guiying Nie; Ke Wang; Jia Wei; Min Zhao; Qi Chen
Journal:  Tumour Biol       Date:  2013-06-28

4.  Expression and localization of serine protease Htra1 in neuroblastoma: correlation with cellular differentiation grade.

Authors:  Velia D'Angelo; Giulia Pecoraro; Paolo Indolfi; Adriana Iannotta; Vittoria Donofrio; Maria Elena Errico; Cristiana Indolfi; Maria Ramaglia; Angela Lombardi; Martina Di Martino; Vincenzo Gigantino; Alfonso Baldi; Michele Caraglia; Antonio De Luca; Fiorina Casale
Journal:  J Neurooncol       Date:  2014-02-04       Impact factor: 4.130

5.  HtrA1 expression associated with the occurrence and development of esophageal cancer.

Authors:  Youtao Yu; Wenlong Shao; Yi Hu; Jingyan Zhang; Hao Song; Zhi-hua Zhu
Journal:  World J Surg Oncol       Date:  2012-08-30       Impact factor: 2.754

6.  HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors.

Authors:  Harmeet Singh; Ying Li; Peter J Fuller; Craig Harrison; Jyothsna Rao; Andrew N Stephens; Guiying Nie
Journal:  J Cancer       Date:  2013-02-01       Impact factor: 4.207

7.  Down-regulation of HtrA1 activates the epithelial-mesenchymal transition and ATM DNA damage response pathways.

Authors:  Ning Wang; Kristin A Eckert; Ali R Zomorrodi; Ping Xin; Weihua Pan; Debra A Shearer; Judith Weisz; Costas D Maranus; Gary A Clawson
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

8.  High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.

Authors:  M Miyamoto; M Takano; K Iwaya; N Shinomiya; T Goto; M Kato; A Suzuki; T Aoyama; J Hirata; I Nagaoka; H Tsuda; K Furuya
Journal:  Br J Cancer       Date:  2015-01-27       Impact factor: 7.640

9.  HtrA1: Its future potential as a novel biomarker for cancer.

Authors:  Emma Altobelli; Daniela Marzioni; Amedeo Lattanzi; Paolo Matteo Angeletti
Journal:  Oncol Rep       Date:  2015-05-28       Impact factor: 3.906

10.  HtrA3 as an early marker for preeclampsia: specific monoclonal antibodies and sensitive high-throughput assays for serum screening.

Authors:  Kemperly Dynon; Sophea Heng; Michelle Puryer; Ying Li; Kelly Walton; Yaeta Endo; Guiying Nie
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.